Skip to main content
Signal8

BioLineRx Ltd. (BLRX) Form 6-K — Nov 18, 2026

$BLRXForm 6-KFiled Nov 18, 2026, 7:07 AM ET0001178913-26-005266Original filing

BioLineRx entered a Purchase and Sale Agreement on November 17, 2026 to sell 80% of its future royalty rights on APHEXDA (motixafortide) net sales to SCOF Motixafortide Holdings, an affiliate of Soleus Capital Management, for a one-time payment of $5.6 million, with closing expected on or about November 30, 2026. The sold interest corresponds to a 14.4% effective royalty on APHEXDA net sales (out of an 18% royalty rate under the Ayrmid license); BioLineRx retains a 3.6% royalty, all milestone payments, and rights under its Asia partnership with Gloria Biosciences.

Key figures

Purchase Price
5600000
Ayrmid royalty rate
18%
Royalty percent sold
80%
Purchaser expense cap
100000
Kreos partial prepayment
3000000
Royalty percent retained
20%
Effective royalty rate sold
14.4%
Kreos remaining outstanding
2000000
Effective royalty rate retained
3.6%
Kreos minimum cash covenant eliminated
4000000

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    BioLineRx Ltd. (BLRX) Form 6-K — Nov 18, 2026: AI Analysis | Signal8